Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oravax
- Development stage
- Unknown
- Lead developer
- Oramed Pharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Oravax is an oral virus-like particle (VLP) vaccine candidate developed by **Oravax Medical** (a joint venture between **Oramed Pharmaceuticals** and **Premas Biotech**) for the prevention of **COVID-19**. The vaccine is unique in its triple-antigen approach, targeting the **Spike (S)**, **Envelope (E)**, and **Membrane (M)** proteins of the SARS-CoV-2 virus, which is intended to provide broader protection against emerging variants compared to single-antigen vaccines. It leverages Oramed's proprietary **POD™ (Protein Oral Delivery)** technology, which uses a specialized capsule to protect the VLP antigens from degradation in the gastrointestinal tract, and Premas Biotech's **D-Crypt™** yeast-based expression platform for VLP production. The oral route of administration aims to eliminate the need for needles and cold-chain storage, potentially increasing global vaccine accessibility.
- Brand names
- Oravax
- Other names
- Oral COVID-19 VaccineOravax oral COVID-19 vaccine
02
Targets
SARS-CoV-2 spikeE (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on Oravax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oravax.